Brent Cameron
Radiation Oncology · Little Rock, ARNPI 1265850325
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,663 of the $2,531 with a category attached, or 65.7%. Teleflex LLC accounts for 72.7% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $1,704, 6.3 times the $269 reported in 2019.
Across 25 payments — averaging $101.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- AstraZeneca$140
- Boston Scientific$128
- Genentech USA, Inc.$127
- E.r. Squibb & Sons, L.L.C.$124
- Dendreon Pharmaceuticals LLC$58
- plus $113 from 6 others
What the payments were for
- Consulting fees$1,66366%
- Food & beverage$86834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 9 | $1,841 |
| AstraZeneca | 2 | $140 |
| Boston Scientific | 4 | $128 |
| Genentech USA, Inc. | 1 | $127 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Dendreon Pharmaceuticals LLC | 2 | $58 |
| Novocure Inc. | 1 | $26 |
| AbbVie | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Blue Earth Diagnostics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,531 in reported general payments places this provider in the 75th percentile of 45 radiation oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 12 | $253 |
| Tamsulosin Hcl | 20 | $148 |
| Dexamethasone | 14 | $79 |
| Lorazepam | 26 | $15 |
| Cephalexin | 27 | $14 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Little Rock
- Fen XiaLittle Rock$4K
- Mausam PatelLittle Rock$3K
- Christopher PopeLittle Rock$2K
- Matthew HardeeLittle Rock$2K
- Mark StoreyLittle Rock$2K
- Leslie HarrellLittle Rock$1K
- Michael MayLittle Rock$1K
- Howard MorganLittle Rock$1K
- Jonathan PaganLittle Rock$1K
- James CordovaLittle Rock$819
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.